Key Points
- Director William Burke sold 32,728 shares of CeriBell on Dec. 9 at an average price of $22.02 for a total of $720,670.56, reducing his stake by 65.30% to 17,391 shares valued at about $382,950.
- CBLL opened at $20.41 with a market cap of $757.2M; the company reported a better‑than‑expected quarter (EPS -$0.37 vs. -$0.43; revenue $22.59M) but remains unprofitable, and analysts have a consensus rating of Moderate Buy with an average target of $25.17.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director William Burke sold 32,728 shares of the firm's stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $22.02, for a total transaction of $720,670.56. Following the completion of the sale, the director directly owned 17,391 shares in the company, valued at approximately $382,949.82. This trade represents a 65.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
CeriBell Stock Performance
Shares of NASDAQ:CBLL opened at $20.41 on Friday. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. The company has a 50-day moving average price of $14.15 and a 200-day moving average price of $14.50. The company has a market cap of $757.21 million, a price-to-earnings ratio of -13.52 and a beta of 1.35. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $32.75.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The company had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. As a group, equities analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current year.
Analyst Upgrades and Downgrades
CBLL has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of CeriBell in a research note on Wednesday, October 8th. TD Cowen dropped their target price on shares of CeriBell from $36.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, November 5th. Raymond James Financial started coverage on shares of CeriBell in a research note on Tuesday, October 21st. They set a "strong-buy" rating and a $19.00 target price on the stock. Cowen reissued a "buy" rating on shares of CeriBell in a research note on Tuesday. Finally, JPMorgan Chase & Co. cut their price objective on CeriBell from $21.00 to $17.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $25.17.
Read Our Latest Research Report on CBLL
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Deutsche Bank AG boosted its holdings in CeriBell by 0.4% in the first quarter. Deutsche Bank AG now owns 231,629 shares of the company's stock worth $4,450,000 after acquiring an additional 842 shares in the last quarter. Swiss National Bank bought a new position in CeriBell in the 1st quarter worth about $467,000. Nuveen LLC purchased a new stake in CeriBell during the 1st quarter valued at about $311,000. Lord Abbett & CO. LLC grew its position in CeriBell by 7.9% during the 1st quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company's stock valued at $6,138,000 after purchasing an additional 23,451 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in CeriBell during the 1st quarter valued at about $175,000.
CeriBell Company Profile
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
